PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM

N/A

Manufactured by Fresenius Kabi USA, LLC

35,839 FDA adverse event reports analyzed

Last updated: 2026-04-14

About PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM

PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Fresenius Kabi USA, LLC. The most commonly reported adverse reactions for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM include DRUG INEFFECTIVE, PYREXIA, ACUTE KIDNEY INJURY, OFF LABEL USE, PNEUMONIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM.

Top Adverse Reactions

DRUG INEFFECTIVE1,592 reports
PYREXIA1,427 reports
ACUTE KIDNEY INJURY1,268 reports
OFF LABEL USE1,145 reports
PNEUMONIA979 reports
SEPSIS863 reports
DIARRHOEA792 reports
THROMBOCYTOPENIA726 reports
DYSPNOEA710 reports
HYPOTENSION709 reports
RASH625 reports
SEPTIC SHOCK603 reports
FEBRILE NEUTROPENIA584 reports
RESPIRATORY FAILURE582 reports
RENAL FAILURE573 reports
CONDITION AGGRAVATED557 reports
NEUTROPENIA543 reports
NAUSEA530 reports
DRUG INTERACTION522 reports
ANAEMIA510 reports
VOMITING500 reports
PANCYTOPENIA432 reports
DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS423 reports
RENAL IMPAIRMENT405 reports
PRODUCT USE IN UNAPPROVED INDICATION390 reports
PAIN383 reports
ABDOMINAL PAIN382 reports
BLOOD CREATININE INCREASED380 reports
DEATH379 reports
RENAL FAILURE ACUTE366 reports
PLATELET COUNT DECREASED363 reports
DRUG HYPERSENSITIVITY357 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME348 reports
PLEURAL EFFUSION342 reports
FATIGUE323 reports
ASTHENIA318 reports
CARDIAC ARREST305 reports
CONFUSIONAL STATE295 reports
URINARY TRACT INFECTION292 reports
PRURITUS288 reports
COUGH287 reports
TACHYCARDIA284 reports
ALANINE AMINOTRANSFERASE INCREASED282 reports
MALAISE281 reports
TUBULOINTERSTITIAL NEPHRITIS281 reports
WHITE BLOOD CELL COUNT DECREASED278 reports
HYPOXIA277 reports
RASH MACULO PAPULAR266 reports
HAEMOGLOBIN DECREASED265 reports
TOXIC EPIDERMAL NECROLYSIS260 reports
CHILLS257 reports
INFECTION257 reports
ASPARTATE AMINOTRANSFERASE INCREASED252 reports
HYPOKALAEMIA251 reports
HYPERTENSION250 reports
ATRIAL FIBRILLATION242 reports
INTERSTITIAL LUNG DISEASE240 reports
RENAL TUBULAR NECROSIS233 reports
DECREASED APPETITE231 reports
EOSINOPHILIA230 reports
HEPATIC FUNCTION ABNORMAL230 reports
LEUKOPENIA227 reports
GENERAL PHYSICAL HEALTH DETERIORATION218 reports
ERYTHEMA217 reports
ACUTE RESPIRATORY DISTRESS SYNDROME215 reports
CELLULITIS214 reports
GASTROINTESTINAL HAEMORRHAGE212 reports
CARDIAC FAILURE211 reports
ACUTE RESPIRATORY FAILURE199 reports
DISSEMINATED INTRAVASCULAR COAGULATION199 reports
HEADACHE199 reports
OEDEMA PERIPHERAL199 reports
TOXICITY TO VARIOUS AGENTS195 reports
CLOSTRIDIUM DIFFICILE INFECTION193 reports
STEVENS JOHNSON SYNDROME191 reports
CLOSTRIDIUM DIFFICILE COLITIS186 reports
DRUG RESISTANCE185 reports
FALL185 reports
LEUKOCYTOSIS182 reports
WEIGHT DECREASED182 reports
ANXIETY180 reports
CYTOKINE RELEASE SYNDROME180 reports
NEPHROPATHY TOXIC180 reports
DEHYDRATION179 reports
HYPERSENSITIVITY179 reports
PULMONARY EMBOLISM179 reports
ANAPHYLACTIC REACTION177 reports
COVID 19176 reports
METABOLIC ACIDOSIS175 reports
MULTI ORGAN FAILURE175 reports
AGRANULOCYTOSIS174 reports
ENCEPHALOPATHY174 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION171 reports
HEPATIC FAILURE171 reports
PNEUMONIA ASPIRATION171 reports
BACK PAIN170 reports
CHEST PAIN170 reports
DIZZINESS169 reports
STAPHYLOCOCCAL INFECTION168 reports
CHOLESTASIS167 reports

Report Outcomes

Out of 18,825 classified reports for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM:

Serious 94.5%Non-Serious 5.5%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male9,984 (57.7%)
Female7,246 (41.9%)
Unknown65 (0.4%)

Reports by Age

Age 71407 reports
Age 63403 reports
Age 74377 reports
Age 64368 reports
Age 70365 reports
Age 69363 reports
Age 65358 reports
Age 61350 reports
Age 68332 reports
Age 58329 reports
Age 67328 reports
Age 66324 reports
Age 72323 reports
Age 62320 reports
Age 60303 reports
Age 76297 reports
Age 73287 reports
Age 56274 reports
Age 75266 reports
Age 57265 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM?

This profile reflects 35,839 FDA FAERS reports that mention PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, PYREXIA, ACUTE KIDNEY INJURY, OFF LABEL USE, PNEUMONIA, SEPSIS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM?

Labeling and FAERS entries often list Fresenius Kabi USA, LLC in connection with PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.